Advertisement

Topics

Deutsche Bank belässt Novartis auf 'Hold' - Ziel 83,50 Franken

10:10 EST 8 Nov 2017 | FinanzNachrichten

Die Deutsche Bank hat die Einstufung für Novartis vor einer Telefonkonferenz zum Bereich Augenheilkunde auf "Hold" mit einem Kursziel von 83,50 Franken belassen. Auf dem Gebiet der altersabhängige...

Related Biotechnology, Pharmaceutical and Healthcare News

Original Article: Deutsche Bank belässt Novartis auf 'Hold' - Ziel 83,50 Franken

NEXT ARTICLE

More From BioPortfolio on "Deutsche Bank belässt Novartis auf 'Hold' - Ziel 83,50 Franken"

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search
Advertisement
 

Relevant Topic

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...


News Quicklinks

Search Biotech, Medical and Healthcare News

Popular Biotech, Medical and Healthcare News

Biotech News by Article Type

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches


BioPortfolio Limited Social Media
Publish Content Agreements
Tools Help

HON Code certificate This site complies with the HONcode standard for trustworthy health information:
Verify here.

The information provided by BioPortfolio.com is not a substitute for professional medical advice, diagnosis or treatment. The BioPortfolio site is sponsored BioPortfolio Limited with offices at Stafford House, 10 Prince of Wales Road, Dorchester, DT1 1PW, England. If you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the boundaries of “Fair Use” and legitimately infringes on your or your client's copyright we may be contacted concerning copyright matters at: priority@bioportfolio.com.
All rights reserved. All other trademarks recognized. Copyright © 1997-2017 BioPortfolio Limited. Site developed by Alacrify Ltd.